Last reviewed · How we verify
NCT05459493
A Clinical Study of Chinese Herbal Compound TJAOA101 in Therapy of Diminished Ovarian Reserve
EARLY_PHASE1 trial testing TJAOA101 in Diminished Ovarian Reserve in 100 participants. Status unknown.
1 November 2023
Quick facts
| Lead sponsor | Tongji Hospital |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 1 November 2022 |
| Primary completion | 1 November 2023 |
| Estimated completion | 1 November 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- TJAOA101 — full drug profile →
Conditions studied
- Diminished Ovarian Reserve — all drugs for Diminished Ovarian Reserve →
Sponsor
Tongji Hospital
Who can join
Adults 18 to 40, female only, with Diminished Ovarian Reserve. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Currently, no drugs have been developed for DOR. We developed the Chinese herbal compound TJAOA101 and has validated its effects in animals. Here, we will perform a population-based, multicenter study to confirm the safety and efficacy of TJAOA101 in therapy of DOR. We aim to provide a solid evidence for TCM in therapy of DOR.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05459493
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of TJAOA101
Trials testing the same drug.
- NCT05522634 — A Clinical Study of Chinese Herbal Compound TJAOA101 in the Treatment of Premature Ovarian Insufficiency · EARLY_PHASE1 · unknown
Other recruiting trials for Diminished Ovarian Reserve
Currently open trials in the same condition.
- NCT07535983 — Bushen Yiqi Formula Combined With Dehydroepiandrosterone in Women With Diminished Ovarian Reserve · Phase 1, PHASE2 · recruiting
- NCT06794047 — The Effect of VitC on IVF Outcome of DOR Patients · NA · recruiting
- NCT07124260 — Characterization of Gut and Tongue Coating Microbiota in Patients With Diminished Ovarian Reserve · recruiting
- NCT06395623 — Study of Acupoints in Diminished Ovarian Reserve Based on Biological Characteristics · recruiting
- NCT06096766 — The Correlation Between Ovarian Function and Serum Biomarkers · recruiting
Other Tongji Hospital trials
Trials by the same sponsor.
- NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
- NCT07537972 — Denosumab Strategy for Liver Cancer With Bone Metastases · Phase 2 · not yet recruiting
- NCT07537959 — Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases · NA · not yet recruiting
- NCT07527260 — Effects of Adenoidectomy on Symptoms and IgE Levels in Children With AR · NA · not yet recruiting
- NCT07524712 — Effects of Energy Versus Mechanical Surgical Devices on Postoperative Cough · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05459493 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tongji Hospital
- Last refreshed: 20 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05459493.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing